Ashwagandha
TL;DR
Most clinically validated Ayurvedic adaptogen. Reduces cortisol via dual HPA-axis mechanisms (NR3C1 allosteric agonism + peripheral HSD11B1 inhibition → no adrenal suppression), uninhibits HPG and HPT axes → testosterone ↑17% (+72 ng/dL) and normalized thyroid in subclinical hypothyroid. Ergogenic via PI3K/AKT/mTOR + eNOS → VO2max ↑4.09 ml/min/kg. Sleep 72% improvement (Shoden, RCT). Multiple extracts — KSM-66 (root-only, daytime), Sensoril (leaf+root, evening), Shoden (sleep, bedtime). Cycling required: 8–12 weeks on / 4 weeks off. Strict contraindications: thyroid disorders, autoimmune disease, CNS polypharmacy.
Why it matters for Vitals
- Cortisol → HRV/readiness: Primary HPA-axis mechanism directly affects resting HRV, sleep onset latency, and morning readiness. Wearable HRV suppression in the 23–32% cortisol reduction range is detectable and coaching-relevant.
- Testosterone → body composition: +17% testosterone effect on free testosterone fraction and SHBG is body-composition relevant. Relevant to male clients on tracking protocols.
- VO2max → aerobic capacity: +4.09 ml/min/kg meta-analysis improvement is meaningful for athletes and is directly trackable via wearables.
- Sleep architecture: 72% clinical insomnia improvement via TEG (triethylene glycol) from Shoden extract — directly observable in sleep efficiency and total sleep time metrics.
- Confound risk: Thyroid stimulation and HPG-axis effects can confound endogenous hormone panels and should be flagged for clients on hormone replacement or thyroid medication.
Key Facts
| Status | OTC — GRAS; extensively RCT-validated |
| Class | Adaptogen / Rasayana (Ayurvedic Rejuvenator) |
| Primary mechanism | HPA-axis: NR3C1 allosteric agonism + HSD11B1 peripheral cortisol inhibition |
| Key benefits | Cortisol ↓19–32%; testosterone ↑17% (+72 ng/dL); VO2max ↑4.09 ml/min/kg; sleep ↑72% (Shoden) |
| Dosing | KSM-66: 300–600 mg/day; Sensoril: 125–250 mg/day; Shoden: 120–240 mg/day at bedtime |
| Cycling | 8–12 weeks on / 4 weeks off (mandatory for GR/NR3C1/GABA receptor sensitivity) |
| Main risks | Thyroid overstimulation; autoimmune exacerbation; SSRI/benzodiazepine CNS over-depression |
| Evidence level | Strong — 15+ RCTs, meta-analyses (n=873 cortisol); multiple sports, endocrine, sleep, cognitive domains |
Mechanism Summary
HPA-axis — two complementary mechanisms:
- NR3C1 allosteric modulation: Withanolides act as partial agonists / competitive antagonists at the glucocorticoid receptor — prevents pathological GR translocation in hypercortisolemia while preserving acute stress response. Does NOT cause adrenal atrophy (unlike exogenous corticosteroids).
- HSD11B1 inhibition: Peripheral 11β-hydroxysteroid dehydrogenase type 1 converts inactive cortisone → active cortisol in adipose and hepatic tissue. Ashwagandha inhibits this → reduces systemic cortisol burden without suppressing adrenal steroidogenesis.
HPG-axis uninhibition: Cortisol ↓ → removes inhibition from Leydig cell testosterone synthesis. Withanolides upregulate StAR protein → drives de novo testosterone from cholesterol. Result: mean +72 ng/dL (+17%, p<0.0001, RCT n=50).
HPT-axis stimulation: Upregulates hepatic 5’-deiodinase → T4 → active T3. Nrf2 protects thyroid follicles from oxidative damage. Normalizes subclinical hypothyroidism (TSH p<0.001, RCT n=50). Biphasic: therapeutic in hypothyroid, iatrogenic thyrotoxicosis in euthyroid at high doses.
PI3K/AKT/mTOR + eNOS: Withaferin A activates PI3K/AKT → ↑ mTOR (muscle protein synthesis) + ↓ PTEN (anti-apoptosis). Same cascade phosphorylates eNOS → ↑ nitric oxide → vasodilation → delayed fatigue onset.
GABA-A allosteric modulation: Ferulate doconasil fraction — enhances benzodiazepine site binding affinity on GABA-A receptor → neuronal hyperpolarization → anxiolysis. Flumazenil antagonizes it → confirms GABA-A dependence.
BDNF upregulation: PI3K/AKT → pCREB → BDNF promoter activation → de novo neurogenesis + synaptic plasticity. Rescues scopolamine-induced amnesia.
Sleep — Triethylene Glycol (TEG): Aqueous leaf extract contains TEG — acts on basal forebrain sleep centers + adenosine receptors. PSG-confirmed: ↑ deep NREM episodes, ↑ sleep efficiency, ↓ sleep onset latency, ↓ WASO.
Nrf2 → antioxidant shield: Withaferin A induces Nrf2 nuclear translocation → SOD, CAT, HO-1, GPx expression → mitochondrial phospholipid protection during high-intensity exercise.
Immunomodulation: TH1 shift (↑ IFN-γ, IL-2, NK cell cytotoxicity); NK CD69 upregulation within 96 h. Telomerase +45% in vitro (HeLa, speculative for human relevance).
Withaferin A → HSP90 inhibition: Disrupts Hsp90-Cdc37 complexes → oncogenic client protein degradation. Active against breast, colon, prostate, ovarian, lung cancer lines. Extreme cytotoxicity — primarily research use; KSM-66 deliberately minimizes WA.
What the current evidence suggests
- Cortisol: 15 RCTs, n=873 — μ = −2.36 µg/dL (95% CI: −3.26 to −1.46, p<0.0001). KSM-66 + Trikatu: 32.1% reduction vs 19% KSM-66 alone.
- Testosterone: +72 ng/dL, +17% (p<0.0001) vs placebo +2% — best available natural testosterone data.
- VO2max: +4.09 ml/min/kg (95% CI: 2.55–5.63, p<0.001); secondary meta: +3.00 ml/min/kg.
- Sleep: 72% clinically significant improvement vs 29% placebo (Shoden, 6-week RCT, actigraphy-confirmed).
- DHEA-S: Significant ↑ (p=0.004) — DHEA-S:cortisol ratio is the primary biomarker of HPA axis resilience.
- Thyroid: T3 ↑ (p=0.003), T4 ↑ (p=0.01), TSH ↓ (p<0.001) in subclinical hypothyroid (n=50, 8 weeks).
Likely Vitals Relevance
| Domain | Expected Signal | Confidence |
|---|---|---|
| HRV | ↑ (cortisol ↓ removes sympathetic tone) | High |
| Sleep efficiency | ↑ (TEG + GABA-A) | High |
| Sleep onset latency | ↓ (GABA-A anxiolysis) | High |
| Resting heart rate | ↓ (cortisol reduction + eNOS vasodilation) | Moderate |
| Morning readiness | ↑ | High |
| Testosterone (males) | ↑ apparent serum total T | High |
| Thyroid (endogenous) | ↑T3/T4, ↓TSH (if hypothyroid) | High |
| VO2max / aerobic capacity | ↑ | Moderate–High |
| Body composition | Improved via testosterone + mTOR + eNOS | Moderate |
Risks and Uncertainty
- Thyroid: Iatrogenic thyrotoxicosis in euthyroid individuals at high doses. Case reports: supraventricular tachycardia, fine tremors. Hashimoto’s and Graves’ strictly contraindicated (TH1 immunostimulation accelerates autoimmune destruction).
- Autoimmune: Strictly contraindicated in RA, SLE, MS — NK cell and TH1 activation directly exacerbates tissue attack.
- CNS polypharmacy: GABA-A allosteric modulation amplifies benzodiazepines → respiratory depression risk. SSRIs + Ashwagandha → theoretical serotonin syndrome.
- HPG-axis: Unknown long-term effects of continuous HPG uninhibition on endogenous testosterone suppression after washout — cycling mitigates.
- Withaferin A cytotoxicity: Leaf extracts with high WA are cytotoxic — KSM-66 is preferred for daily use.
- Pregnancy: Documented abortifacient + spasmogenic uterine effects. Absolute contraindication.
Best Stack Context
| Stack | Rationale |
|---|---|
| + Rhodiola rosea | Stimulating (MAO inhibition) + sedating adaptogen (parasympathetic) — dual-axis energized calm |
| + Shilajit | Fulvic acid drives withanolides into mitochondrial matrix; complementary testosterone synthesis |
| + L-Theanine | Fast α-wave/GABA bridges acute anxiety gap before Ashwagandha steady-state (7–14 d) |
| + BPC-157 | Systemic inflammation reduction + Ashwagandha cortisol effect → optimized tissue repair environment |
| + NMN NAD+ | Ashwagandha ↓ cortisol-mediated NAD+ depletion; preserves SIRT1 activity |
| + Tongkat Ali | Complementary HPG uninhibition (Ashwagandha) + SHBG reduction (Tongkat Ali) |
| + Piperine / BioPerine | CYP3A4 + P-gp inhibition → ↑ withanolide half-life; Trikatu co-administration |
Inside this hub
The following are kept inline rather than as standalone notes:
- Individual withanolide nomenclature (withanolide D, withanone, sitoindosides VII–X, ashwagandhanolide) — compound-specific, not independently retrievable
- NanoAshwagandha nanoparticle pharmacokinetics (single-product detail)
- Phuket sourcing guide — transient market detail
- Full phytochemistry table — reference layer, not retrieval layer
- Individual alkaloid names (somniferin, withanine) — implementation detail
Related notes
- Bacopa monnieri — complementary Ayurvedic nootropic/adaptogen; different mechanism emphasis
- Lion’s Mane — different BDNF pathway (TrkA/TrkB vs PI3K/AKT-CREB); complementary neuroprotection
- BDNF NGF induction — shared BDNF upregulation mechanism; cross-reference for all neurotrophin inducers
- GABA-A receptor — shared GABA-A allosteric site; cross-reference for all modulators
- Rhodiola rosea — complementary stimulating/sedating adaptogen pair
- Shilajit — mitochondrial co-activator stack partner
- Adaptogens MOC — hub map for all adaptogen notes
References
- Cortisol meta-analysis: 15 RCTs, n=873, μ = −2.36 µg/dL
- Testosterone RCT: n=50, +72 ng/dL, +17% (p<0.0001)
- VO2max meta-analysis: +4.09 ml/min/kg (95% CI: 2.55–5.63)
- Shoden sleep RCT: 72% vs 29% placebo, 6-week, actigraphy
- Thyroid RCT: n=50 subclinical hypothyroid, T3/T4/TSH all significant
- KSM-66 + Trikatu: 32.1% cortisol reduction vs 19% alone
- NanoAshwagandha: 38.5× Cmax vs standard 5% extract
- Telomerase: 45% enhancement in vitro (HeLa cells — human relevance uncertain)